Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer.
Diana C DeLuciaThomas M CardilloLisa AngMark P LabrecqueAilin ZhangJames E HopkinsNavonil DeSarkarIlsa ColemanRui Miguel Gil da CostaEva CoreyLawrence D TrueMichael C HaffnerMichael T SchweizerColm MorrisseyPeter S NelsonJohn K LeePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Our findings provide insights into the scope and regulation of CEACAM5 expression in prostate cancer and strong support for clinical studies of labetuzumab govitecan for NEPC.